{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:18:38Z","timestamp":1790986718962,"version":"4.1.0"},"reference-count":59,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We investigated deposition of the complement protein fragment C3b and its breakdown products (collectively designated as C3b(i)) on CD20-positive cells treated with rituximab (RTX) in the presence of normal human serum (NHS). Radioimmunoassay (RIA) demonstrates that about 500\u2009000 C3b(i) molecules deposit per cell, and fluorescence microscopy reveals that C3b(i) colocalizes with bound RTX. Use of mAb 3E7, specific for C3b(i) bound to substrates, enhances C3b(i) deposition; &gt; 1 million C3b(i) deposit when cells are incubated with NHS, RTX and mAb 3E7. Treatment of Raji cells in NHS plus RTX leads to robust cell killing (95%) after 24 to 48 hours, and mAb 3E7 significantly enhances RTX-mediated killing of Raji and DB cells. A cynomolgus monkey model based on intravenous infusion of RTX followed by mAb 3E7 demonstrated that RTX rapidly binds to B cells and promotes complement activation and C3b(i) deposition; fluorescence microscopy analyses revealed the same pattern of colocalization of C3b(i) on cell-bound RTX in vivo as observed in vitro. Preliminary in vitro studies with blood samples from patients with chronic lymphocytic leukemia lead to similar findings. These experiments suggest that complement plays a key role in the mechanism of action of RTX; moreover, the in vivo molecular form of RTX (and possibly other antitumor mAbs) in the circulation or in tissues may include C3b(i) molecules covalently bound to the therapeutic mAb, thus allowing it to interact with cells containing both Fc and complement receptors.<\/jats:p>","DOI":"10.1182\/blood-2002-03-0876","type":"journal-article","created":{"date-parts":[[2003,1,15]],"date-time":"2003-01-15T21:05:10Z","timestamp":1042664710000},"page":"1071-1079","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":104,"title":["An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab"],"prefix":"10.1182","volume":"101","author":[{"given":"Adam D.","family":"Kennedy","sequence":"first","affiliation":[{"name":"From the Department of Biochemistry and Molecular Genetics, the Department of Cell Biology, and the Center for Comparative Medicine, University of Virginia Health Sciences Center, Charlottesville."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Solga","sequence":"additional","affiliation":[{"name":"From the Department of Biochemistry and Molecular Genetics, the Department of Cell Biology, and the Center for Comparative Medicine, University of Virginia Health Sciences Center, Charlottesville."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore A.","family":"Schuman","sequence":"additional","affiliation":[{"name":"From the Department of Biochemistry and Molecular Genetics, the Department of Cell Biology, and the Center for Comparative Medicine, University of Virginia Health Sciences Center, Charlottesville."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos W.","family":"Chi","sequence":"additional","affiliation":[{"name":"From the Department of Biochemistry and Molecular Genetics, the Department of Cell Biology, and the Center for Comparative Medicine, University of Virginia Health Sciences Center, Charlottesville."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Lindorfer","sequence":"additional","affiliation":[{"name":"From the Department of Biochemistry and Molecular Genetics, the Department of Cell Biology, and the Center for Comparative Medicine, University of Virginia Health Sciences Center, Charlottesville."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Sutherland","sequence":"additional","affiliation":[{"name":"From the Department of Biochemistry and Molecular Genetics, the Department of Cell Biology, and the Center for Comparative Medicine, University of Virginia Health Sciences Center, Charlottesville."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L.","family":"Foley","sequence":"additional","affiliation":[{"name":"From the Department of Biochemistry and Molecular Genetics, the Department of Cell Biology, and the Center for Comparative Medicine, University of Virginia Health Sciences Center, Charlottesville."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald P.","family":"Taylor","sequence":"additional","affiliation":[{"name":"From the Department of Biochemistry and Molecular Genetics, the Department of Cell Biology, and the Center for Comparative Medicine, University of Virginia Health Sciences Center, Charlottesville."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111611545307600_B1","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","article-title":"Complement.","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med."},{"key":"2019111611545307600_B2","first-page":"1","article-title":"The complement system: a brief overview.","volume-title":"Complement Regulatory Proteins.","author":"Morgan","year":"1999"},{"key":"2019111611545307600_B3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1201\/b14212-3","article-title":"Overview of the complement system.","volume-title":"The Human Complement System in Health and Disease.","author":"Volanakis","year":"1998"},{"key":"2019111611545307600_B4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1201\/b14212-6","article-title":"The chemistry and biology of C3, C4 and C5.","volume-title":"The Human Complement System in Health and Disease.","author":"Lambris","year":"1998"},{"key":"2019111611545307600_B5","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s002620000140","article-title":"Targeting of cancer cells with monoclonal antibodies specific for C3b(i).","volume":"49","author":"Sokoloff","year":"2000","journal-title":"Cancer Immunol Immunother."},{"key":"2019111611545307600_B6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0162-3109(99)00013-2","article-title":"Therapeutic intervention with complement and \u03b2-glucan in cancer.","volume":"42","author":"Ross","year":"1999","journal-title":"Immunopharmacology."},{"key":"2019111611545307600_B7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1126\/science.186.4162.454","article-title":"Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells.","volume":"186","author":"Irie","year":"1974","journal-title":"Science."},{"key":"2019111611545307600_B8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1172\/JCI118777","article-title":"Soluble \u03b2-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b\/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.","volume":"98","author":"Vetvicka","year":"1996","journal-title":"J Clin Invest."},{"key":"2019111611545307600_B9","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0167-5699(99)01537-6","article-title":"Immune evasion of tumor cells using membrane-bound complement regulatory proteins.","volume":"20","author":"Gorter","year":"1999","journal-title":"Immunol Today."},{"key":"2019111611545307600_B10","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0161-5890(99)00115-7","article-title":"Complement resistance of tumor cells: basal and induced mechanisms.","volume":"36","author":"Jurianz","year":"1999","journal-title":"Mol Immunol."},{"key":"2019111611545307600_B11","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s001090050144","article-title":"Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy.","volume":"75","author":"Springer","year":"1997","journal-title":"J Mol Med."},{"key":"2019111611545307600_B12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1046\/j.1365-2567.1998.00429.x","article-title":"The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells.","volume":"93","author":"Olesen","year":"1998","journal-title":"Immunology."},{"key":"2019111611545307600_B13","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.4049\/jimmunol.158.11.5455","article-title":"A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.","volume":"158","author":"Schwendinger","year":"1997","journal-title":"J Immunol."},{"key":"2019111611545307600_B14","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.","volume":"19","author":"Byrd","year":"2001","journal-title":"J Clin Oncol."},{"key":"2019111611545307600_B15","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood."},{"key":"2019111611545307600_B16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood."},{"key":"2019111611545307600_B17","first-page":"66","article-title":"Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.","volume":"26","author":"Grillo-Lopez","year":"1999","journal-title":"Semin Oncol."},{"key":"2019111611545307600_B18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.","volume":"17","author":"Czuczman","year":"1999","journal-title":"Clin Oncol."},{"key":"2019111611545307600_B19","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood."},{"key":"2019111611545307600_B20","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol."},{"key":"2019111611545307600_B21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med."},{"key":"2019111611545307600_B22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0022-2143(99)90164-6","article-title":"Clinical applications of anti-CD20 antibodies.","volume":"134","author":"Gopal","year":"1999","journal-title":"J Lab Clin Med."},{"key":"2019111611545307600_B23","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood.V97.5.1392","article-title":"Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.","volume":"97","author":"Ghetie","year":"2001","journal-title":"Blood."},{"key":"2019111611545307600_B24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s002620050016","article-title":"Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.","volume":"48","author":"Shan","year":"2000","journal-title":"Cancer Immunol Immunother."},{"key":"2019111611545307600_B25","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.","volume":"91","author":"Shan","year":"1998","journal-title":"Blood."},{"key":"2019111611545307600_B26","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc\u03b3RIIa gene.","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood."},{"key":"2019111611545307600_B27","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","article-title":"The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.","volume":"99","author":"Byrd","year":"2002","journal-title":"Blood."},{"key":"2019111611545307600_B28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.","volume":"83","author":"Reff","year":"1994","journal-title":"Blood."},{"key":"2019111611545307600_B29","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.4049\/jimmunol.164.8.4178","article-title":"Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 Fc.","volume":"164","author":"Idusogie","year":"2000","journal-title":"J Immunol."},{"key":"2019111611545307600_B30","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.4049\/jimmunol.166.4.2571","article-title":"Engineered antibodies with increased activity to recruit complement.","volume":"166","author":"Idusogie","year":"2001","journal-title":"J Immunol."},{"key":"2019111611545307600_B31","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1365-3083.2000.00745.x","article-title":"Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.","volume":"51","author":"Harjunpa\u0308a\u0308","year":"2000","journal-title":"Scand J Immunol."},{"key":"2019111611545307600_B32","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis.","volume":"95","author":"Golay","year":"2000","journal-title":"Blood."},{"key":"2019111611545307600_B33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/cimm.2000.1693","article-title":"Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines.","volume":"204","author":"Flieger","year":"2000","journal-title":"Cell Immunol."},{"key":"2019111611545307600_B34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002371-200105000-00011","article-title":"Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.","volume":"24","author":"Treon","year":"2001","journal-title":"J Immunother."},{"key":"2019111611545307600_B35","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood.V98.9.2771","article-title":"Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species.","volume":"98","author":"Bellosillo","year":"2001","journal-title":"Blood."},{"key":"2019111611545307600_B36","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","article-title":"CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.","volume":"98","author":"Golay","year":"2001","journal-title":"Blood."},{"key":"2019111611545307600_B37","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1046\/j.1365-2141.2001.03166.x","article-title":"Complement activations plays a key role in the side-effects of rituximab treatment.","volume":"115","author":"van der Kolk","year":"2001","journal-title":"Br J Haematol."},{"key":"2019111611545307600_B38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0022-1759(89)90248-2","article-title":"Preparation of monoclonal antibodies to C3b by immunization with C3b(i)-sepharose.","volume":"120","author":"Tosic","year":"1989","journal-title":"J Immunol Methods."},{"key":"2019111611545307600_B39","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.4049\/jimmunol.141.12.4258","article-title":"Quantitative analyses of the relationship between C3 consumption, C3b capture, and immune adherence of complement-fixing antibody\/DNA immune complexes.","volume":"141","author":"Edberg","year":"1988","journal-title":"J Immunol."},{"key":"2019111611545307600_B40","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/0006-291X(78)91322-0","article-title":"Protein and cell membrane iodinations with a sparingly soluble choloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycol uril.","volume":"80","author":"Fraker","year":"1978","journal-title":"Biochem Biophys Res Commun."},{"key":"2019111611545307600_B41","first-page":"354","volume-title":"Antibodies: A Laboratory Manual.","author":"Harlow","year":"1988"},{"key":"2019111611545307600_B42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1034\/j.1600-065x.2001.1830102.x","article-title":"Heteropolymer-mediated clearance of immune complexes via erythrocyte CR1: mechanisms and applications.","volume":"183","author":"Lindorfer","year":"2001","journal-title":"Immunol Rev."},{"key":"2019111611545307600_B43","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1006\/clim.1999.4739","article-title":"Infusion of bispecific monoclonal antibody complexes into monkeys provides immunologic protection against later challenge with a model pathogen.","volume":"92","author":"Craig","year":"1999","journal-title":"Clin Immunol."},{"key":"2019111611545307600_B44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj2640001","article-title":"Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects.","volume":"264","author":"Morgan","year":"1989","journal-title":"Biochem J."},{"key":"2019111611545307600_B45","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V69.2.584.584","article-title":"Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas.","volume":"69","author":"Press","year":"1987","journal-title":"Blood."},{"key":"2019111611545307600_B46","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1074\/jbc.273.1.344","article-title":"Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment.","volume":"273","author":"Deans","year":"1998","journal-title":"J Biol Chem."},{"key":"2019111611545307600_B47","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.4049\/jimmunol.165.10.5954","article-title":"Triggering Fc\u03b1-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.","volume":"165","author":"Stockmeyer","year":"2000","journal-title":"J Immunol."},{"key":"2019111611545307600_B48","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V98.5.1352","article-title":"Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.","volume":"98","author":"Weng","year":"2001","journal-title":"Blood."},{"key":"2019111611545307600_B49","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0161-5890(01)00055-4","article-title":"Complement and apoptosis.","volume":"38","author":"Fishelson","year":"2001","journal-title":"Mol Immunol."},{"key":"2019111611545307600_B50","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1042\/bj1950471","article-title":"The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.","volume":"195","author":"Gadd","year":"1981","journal-title":"Biochem J."},{"key":"2019111611545307600_B51","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4049\/jimmunol.131.1.409","article-title":"The interaction of C3b bound to Pneumococci with factor H (beta 1H globulin), factor I (C3b\/C4b inactivator), and properdin factor B of the human complement system.","volume":"131","author":"Brown","year":"1983","journal-title":"J Immunol."},{"key":"2019111611545307600_B52","doi-asserted-by":"crossref","first-page":"38217","DOI":"10.1074\/jbc.M104870200","article-title":"Serine 132 is the C3 covalent attachment point on the CH1 domain of human IgG1.","volume":"276","author":"Vidarte","year":"2001","journal-title":"J Biol Chem."},{"key":"2019111611545307600_B53","doi-asserted-by":"crossref","first-page":"18520","DOI":"10.1016\/S0021-9258(18)55092-4","article-title":"Localization of the human complement C3 binding site on the IgG heavy chain.","volume":"266","author":"Shohet","year":"1991","journal-title":"J Biol Chem."},{"key":"2019111611545307600_B54","first-page":"45","article-title":"Phagocytosis of target particles bearing C3b-IgG covalent complexes by human monocytes and polymorphonuclear leucocytes.","volume":"62","author":"Fries","year":"1987","journal-title":"Immunology."},{"key":"2019111611545307600_B55","first-page":"405","article-title":"The complement fragment C3d facilitates phagocytosis by monocytes.","volume":"62","author":"Gaither","year":"1987","journal-title":"Immunology."},{"key":"2019111611545307600_B56","first-page":"43","article-title":"Myeloid cell-targeted cytotoxicity of tumor cells.","volume-title":"Bispecific Antibodies.","author":"Wallace","year":"1995"},{"key":"2019111611545307600_B57","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3109\/10428199909058437","article-title":"Hypocomplementemia in multiple myeloma.","volume":"33","author":"Lugassy","year":"1999","journal-title":"Leuk Lymphoma."},{"key":"2019111611545307600_B58","first-page":"1509","article-title":"The complement system is defective in chronic lymphatic patients and in healthy relatives.","volume":"10","author":"Schlesinger","year":"1996","journal-title":"Leukemia."},{"key":"2019111611545307600_B59","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s002620000096","article-title":"Functional assessment in vitro of human-complement-dependent antibody-induced cytotoxicity of neoplastic cells.","volume":"49","author":"Brezicka","year":"2000","journal-title":"Cancer Immunol Immunother."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/3\/1071\/1260153\/h80303001071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/3\/1071\/1260153\/h80303001071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T10:29:03Z","timestamp":1682332143000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/101\/3\/1071\/88860\/An-antiC3bi-mAb-enhances-complement-activation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,1]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-03-0876","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2003,2,1]]}}}